
Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Free Report) – Research analysts at HC Wainwright lowered their FY2026 earnings per share estimates for Greenwich LifeSciences in a note issued to investors on Wednesday, November 18th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($1.46) per share for the year, down from their previous estimate of ($1.29). HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Greenwich LifeSciences’ current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Greenwich LifeSciences’ Q4 2026 earnings at ($0.41) EPS, Q1 2027 earnings at ($0.37) EPS, Q2 2027 earnings at ($0.37) EPS, Q3 2027 earnings at ($0.36) EPS, Q4 2027 earnings at ($0.36) EPS and FY2027 earnings at ($1.46) EPS.
Greenwich LifeSciences (NASDAQ:GLSI – Get Free Report) last posted its earnings results on Monday, November 16th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.06).
Read Our Latest Analysis on Greenwich LifeSciences
Greenwich LifeSciences Trading Down 1.6%
Shares of NASDAQ:GLSI opened at $19.48 on Friday. The company has a 50 day moving average of $16.87 and a 200 day moving average of $20.77. The stock has a market cap of $285.95 million, a P/E ratio of 0.00 and a beta of 1.57. Greenwich LifeSciences has a 12 month low of $7.78 and a 12 month high of $34.10.
Hedge Funds Weigh In On Greenwich LifeSciences
Institutional investors have recently added to or reduced their stakes in the company. Ancora Advisors LLC boosted its position in shares of Greenwich LifeSciences by 101.2% in the 3rd quarter. Ancora Advisors LLC now owns 21,610 shares of the company’s stock worth $390,000 after purchasing an additional 10,870 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Greenwich LifeSciences by 44.4% during the 3rd quarter. Goldman Sachs Group Inc. now owns 56,793 shares of the company’s stock valued at $1,025,000 after buying an additional 17,464 shares in the last quarter. BlackRock Inc. bought a new position in Greenwich LifeSciences during the 2nd quarter valued at approximately $11,398,000. Deutsche Bank AG purchased a new position in Greenwich LifeSciences during the second quarter valued at $126,000. Finally, Bank of New York Mellon Corp purchased a new stake in Greenwich LifeSciences during the 2nd quarter valued at about $1,124,000. Institutional investors own 4.16% of the company’s stock.
Trending Headlines about Greenwich LifeSciences
These are some of the GLSI headlines that stood out recently:
- Positive Sentiment: HC Wainwright maintained a Buy rating and raised its price target to $70. Article: Greenwich LifeSciences Stock Gets Price Target Boost from HC Wainwright
- Negative Sentiment: HC Wainwright lowered its 2026 and 2027 EPS forecasts, including FY2026 from a loss of $1.29 to $1.46 per share and FY2027 from a loss of $1.17 to $1.46. Noble Financial estimates losses of $1.49 per share in 2026 and $2.14 in 2027, suggesting ongoing cash burn and weaker projected earnings. Greenwich LifeSciences analyst estimates
About Greenwich LifeSciences
Greenwich LifeSciences, Inc. is a clinical-stage biotechnology company developing immunotherapies intended to reduce the risk of breast cancer recurrence. The company’s work centers on GP2, an investigational peptide-based vaccine designed for patients with HER2/neu-positive breast cancer who have completed standard treatment. GP2 is intended to stimulate an immune response against cancer cells expressing HER2/neu and is administered with the immune-system stimulant GM-CSF. Greenwich LifeSciences is evaluating the candidate in clinical trials; it does not have an approved commercial product.
Read More
- Five stocks we like better than Greenwich LifeSciences
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
